Abstract
This review documents the evolution of surfactant therapy, beginning with observations of surfactant deficiency in respiratory distress syndrome, the basis of exogenous surfactant treatment and the development of surfactant-containing novel peptides patterned after SP-B. We critically analyse the molecular interactions of surfactant proteins and phospholipids contributing to surfactant function.
Conclusion:
Peptide-containing surfactant provides clinical efficacy in the treatment of respiratory distress syndrome and offers promise for treating other lung diseases in infancy.
MeSH terms
-
Clinical Trials as Topic
-
Drug Combinations
-
Fatty Alcohols / therapeutic use
-
Humans
-
Hydrophobic and Hydrophilic Interactions
-
Infant, Newborn
-
Intensive Care, Neonatal / trends
-
Lung Diseases / drug therapy
-
Peptides / therapeutic use
-
Phosphatidylglycerols / therapeutic use
-
Phospholipids / therapeutic use
-
Proteins / therapeutic use
-
Pulmonary Alveoli / physiology
-
Pulmonary Surfactant-Associated Proteins / physiology
-
Pulmonary Surfactant-Associated Proteins / therapeutic use*
-
Pulmonary Surfactants / chemistry
-
Pulmonary Surfactants / pharmacology
-
Pulmonary Surfactants / therapeutic use*
-
Respiratory Distress Syndrome, Newborn / drug therapy*
Substances
-
Drug Combinations
-
Fatty Alcohols
-
Peptides
-
Phosphatidylglycerols
-
Phospholipids
-
Proteins
-
Pulmonary Surfactant-Associated Proteins
-
Pulmonary Surfactants
-
lucinactant